CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced that members of its senior management will participate in a fireside chat at the upcoming Piper Sandler 36th Annual Healthcare...
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the third quarter and nine months ended September 30, 2024. “We are proud to report our record-breaking quart...
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its third quarter 2024 financial results before the open of the U.S. financial markets on Friday...
Xeris Biopharma Holdings, Inc. is an overlooked specialty pharmaceutical company with three FDA-approved products, utilizing its proprietary XeriSol and XeriJect technologies to develop innovative injectable drug formulations. Gvoke and Recorlev drive Xeris' rapid growth, with Gvoke holding 34% of the retail glucagon market and Recorlev expanding its patient base by 124%. Xeris' strategic partn...
The 'Undercovered' Dozen highlights 12 lesser-covered stocks from October 4th - 10th, aiming to inspire discussion and provide investment ideas. WW International's pivot to GLP-1 medications raises concerns for Dilantha De Silva about growth and customer churn, leading to a bearish stance despite recent stock gains. Fresenius Medical Care shows Wolf Report potential for growth despite recent ea...
Xeris Biopharma is trading above my Buy Threshold of $2.76 and is nearing a potential breakout above the $3.25 resistance level. The company shows strong revenue growth, driven by products like Gvoke and Recorlev, despite not yet reporting a positive EPS. Risks include intense competition and potential need for additional funding, but projected revenue growth suggests significant upside potential.
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on October 1, 2024, the Compensation Committee of Xeris' Board of Directors granted restricted stock units for an aggregate...
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.